Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
| Revenue (TTM) | $1.65B |
| Gross Profit (TTM) | $937.07M |
| EBITDA | $316.92M |
| Operating Margin | 9.62% |
| Return on Equity | -0.70% |
| Return on Assets | 2.83% |
| Revenue/Share (TTM) | $21.41 |
| Book Value | $13.41 |
| Price-to-Book | 1.19 |
| Price-to-Sales (TTM) | 0.76 |
| EV/Revenue | 1.81 |
| EV/EBITDA | 12.16 |
| Quarterly Earnings Growth (YoY) | 0.40% |
| Quarterly Revenue Growth (YoY) | 0.80% |
| Shares Outstanding | $77.77M |
| Float | $58.68M |
| % Insiders | 14.30% |
| % Institutions | 98.67% |
Volatility is currently expanding
Company to feature surgeon-led educational programming and technologies supporting liver surgery Company to feature surgeon-led educational programming and technologies supporting liver surgery
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Michael McBreen, chief commercial officer, will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 2:15 p.m. ET. Stuart Essig, chairman and chief executive officer, will present at the 2026 Morgan Stanley Healthcare Conference on Tuesday, September 15, 2026, at 4:05 p.m. ET.
Integra LifeSciences Holdings is a turnaround story, maintaining a BUY rating after a strong 2Q26 earnings beat and margin expansion. IART's specialty surgery segment led revenue, while tissue reconstruction saw declines offset by a successful PriMatrix relaunch and upcoming SurgiMend reintroduction. Management targets leverage reduction to 2.5–3.5x by end-2026, prioritizing debt repayment as operating cash flow improves.
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IART and any ticker you trade — then tracks every position and per-strategy win rate.
